Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20711845 | 0.84 | ALDH1A1 (0.32) | SLC6A11TDP1L3MBTL1MCHR1CHRM3 | |
| SCHEMBL21482242 | 0.84 | CHRM3 (0.33) | SLC6A11TDP1L3MBTL1MCHR1CHRM3 | |
| SCHEMBL12188157 | 0.68 | CHRM3 (0.41) | L3MBTL1CHRM3ALDH1A1MAPT | |
| SCHEMBL21429859 | 0.68 | CHRM3 (0.41) | L3MBTL1CHRM3ALDH1A1MAPT | |
| SCHEMBL12522315 | 0.67 | RAB9A (0.40) | — | |
| SCHEMBL19265714 | 0.67 | RAB9A (0.40) | — | |
| SCHEMBL19190098 | 0.67 | SLC6A11 (0.36) | SLC6A11MCHR1 | |
| SCHEMBL16901707 | 0.67 | SLC6A11 (0.36) | SLC6A11MCHR1 | |
| SCHEMBL16901708 | 0.67 | SLC6A11 (0.36) | SLC6A11MCHR1 | |
| SCHEMBL19026920 | 0.67 | MAPT (0.38) | L3MBTL1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190315724-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315724-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | SLC6A11 2254/4885TDP1 3099/4885L3MBTL1 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.